Literature DB >> 17947637

How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies.

Kalet Leon1, Karina Garcia, Jorge Carneiro, Agustin Lage.   

Abstract

Aiming to get a better insight on the impact of regulatory CD25(+)CD4(+) T cells in tumor-immunobiology, a simple mathematical model was previously formulated and studied. This model predicts the existence of two alternative modes of uncontrolled tumor growth, which differ on their coupling with the immune system, providing a plausible explanation to the observation that the development of some tumors expand regulatory T cells whereas others do not. We report now the study of how these two tumor classes respond to different therapies, namely vaccination, immune suppression, surgery, and their different combinations. We show 1) how the timing and the dose applied in each particular treatment determine whether the tumor will be rejected, with or without concomitant autoimmunity, or whether it will continue progressing with slower or faster pace; 2) that both regulatory T cell-dependent and independent tumors are equally sensitive to vaccination, although the former are more sensitive to T cell depletion treatments and are unresponsive to partial surgery alone; 3) that surgery, suppression, and vaccination treatments, can synergistically improve their individual effects, when properly combined. Particularly, we predict rational combinations helping to overcome the limitation of these individual treatments on the late stage of tumor development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947637     DOI: 10.4049/jimmunol.179.9.5659

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  T cell state transition produces an emergent change detector.

Authors:  Peter S Kim; Peter P Lee
Journal:  J Theor Biol       Date:  2011-01-27       Impact factor: 2.691

2.  A theory of immunodominance and adaptive regulation.

Authors:  Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2010-10-01       Impact factor: 1.758

3.  Emergent group dynamics governed by regulatory cells produce a robust primary T cell response.

Authors:  Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2009-12-16       Impact factor: 1.758

4.  Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.

Authors:  Natalie Kronik; Yuri Kogan; Moran Elishmereni; Karin Halevi-Tobias; Stanimir Vuk-Pavlović; Zvia Agur
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

5.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

6.  Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells.

Authors:  Yoo Jin Choi; Kwang Mo Yang; Sung Dae Kim; Young Hyun Yoo; Sang Wha Lee; Su Yeong Seo; Hongsuk Suh; Sung Tae Yee; Min Ho Jeong; Wol Soon Jo
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

7.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300

8.  Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach.

Authors:  Peter S Kim; Peter P Lee
Journal:  PLoS Comput Biol       Date:  2012-10-25       Impact factor: 4.475

Review 9.  Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models.

Authors:  Marta Caridade; Luis Graca; Ruy M Ribeiro
Journal:  Front Immunol       Date:  2013-11-18       Impact factor: 7.561

10.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-Regulated Immune System Driven by an Interplay Between Regulatory T Cells and Chronic Human Herpesvirus Infections.

Authors:  Nuno Sepúlveda; Jorge Carneiro; Eliana Lacerda; Luis Nacul
Journal:  Front Immunol       Date:  2019-11-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.